Additionally, FGF23 and phosphate have emerged as relevant factors in cancer pathophysiology, particularly in cancer types with implications for bone health such as bone sarcoma, multiple myeloma, or those associated with bone metastases. This evidence concerns the gene FGF23 and plasma cell myeloma.